Chemotherapy‐induced alopecia – the urgent need for treatment options

Sikora, Mariusz; Rudnicka, Lidia

doi:10.1111/jdv.15207

Cited by 5 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PRP has been used as an autologous injection for various medical conditions to promote healing and tissue regeneration/rejuvenation [ 73 , 74 , 75 , 76 , 77 , 78 ]. Additionally, PRP has also been used widely in alopecia treatment due to its ability to induce cell proliferation, supporting HF growth, and extending anagen [ 72 , 79 , 80 , 81 , 82 ]. Whereas PRP treatment has the advantages of minimal invasiveness, low cost, and being autologous, its effectiveness has not been vigorously validated, partly due to the autologous nature and partly due to the variations in preparation protocols [ 83 ].…”

Section: Cia Treatmentmentioning

confidence: 99%

Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?

et al. 2023

View full text Add to dashboard Cite

Millions of new cancer patients receive chemotherapy each year. In addition to killing cancer cells, chemotherapy is likely to damage rapidly proliferating healthy cells, including the hair follicle keratinocytes. Chemotherapy causes substantial thinning or loss of hair, termed chemotherapy-induced alopecia (CIA), in approximately 65% of patients. CIA is often ranked as one of the most distressing adverse effects of chemotherapy, but interventional options have been limited. To date, only scalp cooling has been cleared by the US Food and Drug Administration (FDA) to prevent CIA. However, several factors, including the high costs not always covered by insurance, preclude its broader use. Here we review the current options for CIA prevention and treatment and discuss new approaches being tested. CIA interventions include scalp cooling systems (both non-portable and portable) and topical agents to prevent hair loss, versus topical and oral minoxidil, photobiomodulation therapy (PBMT), and platelet-rich plasma (PRP) injections, among others, to stimulate hair regrowth after hair loss. Evidence-based studies are needed to develop and validate methods to prevent hair loss and/or accelerate hair regrowth in cancer patients receiving chemotherapy, which could significantly improve cancer patients’ quality of life and may help improve compliance and consequently the outcome of cancer treatment.

show abstract

Section: Cia Treatmentmentioning

confidence: 99%

Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The precise molecular process underpinning the phenomenon of chemotherapy-induced alopecia (CIA) remains elusive and requires further investigation. The fundamental concepts for mitigating CIA involve minimizing the delivery of chemotherapeutic agents to the hair follicle and employing pharmaceutical interventions to facilitate hair regrowth [ 5 ]. Nevertheless, a viable solution to mitigate this issue has yet to be devised [ 2 , 4 ].…”

Section: Introductionmentioning

confidence: 99%